AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 15 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Greater availability of the new pneumococcal conjugate vaccine to children in developing countries could not only reduce morbidity and mortality but also limit the impact of antibiotic resistance among pneumococci worldwide.
M.H. Kyaw and associates in Scotland outlined the advantages of the new vaccines in a letter to Acta Paediatrica.
The vaccines include seven to 11 serotypes, which are the most common cause of pediatric disease in most parts of the world, noted Kyaw and colleagues. Research has shown the efficacy of a 7-valent conjugate vaccine to be 97.4% (95% confidence interval [CI], 82.7-99.9) against invasive pneumococcal disease and 57% (95% CI, 44-67) against otitis media caused by vaccine serotypes, they pointed out.
Pneumococcal disease is a major cause of morbidity and mortality in infants and young children worldwide, but this vaccine has the potential to prevent pneumonia and has also been shown to reduce nasopharyngeal carriage of vaccine serotypes, particularly those associated with antibiotic resistance, Kyaw and coworkers stated.
Its widespread use, therefore, could substantially reduce the burden of invasive disease and potentially ...
Source: HighBeam Research, Better Worldwide Access To Pneumococcal Vaccines Is Needed.